We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said it is ending the development of pimodivir, an investigational antiviral treatment for influenza A infection, after disappointing study results.
Janssen said interim analyses of a Phase 3 study in hospitalized patients with influenza A found that pimodivir in combination with the standard of care was very unlikely to show an added benefit compared to standard-of-care treatment alone.
The company said it is halting the trial in hospitalized patients, along with a parallel study in outpatients with influenza A.
Janssen licensed pimodivir in 2014 from Boston drug maker Vertex Pharmaceuticals Inc. in a deal that included an upfront payment of $30 million, along with contingent development and commercial milestone payments.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 02, 2020 09:38 ET (13:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
